Stock Price & Analysis

Based on the analysis of Surgery Partners (SGRY), here is the recommendation:

Buy SGRY stock as strong analyst consensus and revenue growth outweigh current concerns.

Surgery Partners (SGRY) is expected to reach a price target of $28 to $35 in 2025, driven by its strong position in the healthcare sector and positive analyst outlooks. The stock currently trades at $24.99, with a consensus Strong Buy rating and an average price target of $32.67, indicating significant upside potential. However, profitability challenges and negative insider sentiment may limit near-term gains.

The S1 support level for SGRY Stock is $23.46 ,The R1 resistant level for SGRY Stock is $24.5.

As of the end of day on 2025-03-26, the price of SGRY Stock was $24.05.

The target price for SGRY Stock according to analyst rating is 32.63, with the highest price target at 36.00 and the lowest at 28.00. Analysts have a Strong Buy rating on SGRY Stock overall.

The market cap of SGRY is $3.1B.

SGRY appears overvalued based on its high valuation multiples and inconsistent profitability. Despite revenue growth (Q1-Q3 2024: $717.4M, $762.1M, $770.4M), the company reported net losses each quarter (-$12.4M, -$15.5M, -$31.7M), indicating rising operational costs. With an EV/EBITDA of 14.31x and P/S of 1.36x, SGRY's valuation exceeds industry averages. Analysts maintain a Strong Buy consensus with a $32.67 target, but negative insider sentiment and increasing losses raise concerns about its current price.

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. Its segments include Surgical Facility Services and Ancillary Services. The Surgical Facility Services segment consists of the operation of ASCs and surgical hospitals and includes its anesthesia services. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology and general surgery. The Ancillary Services segment consisted of multi-specialty physician practices, including physician practices owned and operated pursuant to long-term management service agreements. It is focused on surgical services businesses in the United States, with over 180 locations in 33 states, including ambulatory surgery centers, short-stay surgical hospitals, and multi-specialty physician practices.

Surgery Partners (SGRY) stock is predicted to reach $35 by 2030, driven by strong buyout interest from Bain Capital and its solid financial performance. The current price of $24.99 reflects undervaluation, with potential for significant upside.

SGRY has a total of 10500 employees.